UPPI Members and Invited Vendors are encouraged to book hotel accommodations as soon as possible. An exciting and full program is planned for the upcoming event. Please see Michelle Thompson at mthompson@uppi.org for details on attending and agenda.
Register here.
HAMILTON, ON, Feb. 22, 2024 /PRNewswire/ – AtomVie Global Radiopharma Inc. (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), is proud to announce strategic collaborations with RLS Radiopharmacies and UPPI LLC. (UPPI), two industry leaders in radiopharmacy and logistics. This strategic move is poised to enhance AtomVie’s logistics capabilities within the United States, ensuring the widespread distribution of high-quality radiopharmaceuticals by implementing RLS and UPPI as key partners within AtomVie’s existing U.S. distribution network. AtomVie specializes in the GMP manufacturing and global distribution of radiopharmaceuticals, RLS the only Joint Commission-accredited radiopharmacy network in the U.S., owns and operates 31 radiopharmacies covering more than 80% of the United States population, and UPPI, organized as a Group Purchasing Organization (GPO), brings extensive capabilities in logistics and distribution.
Radiopharmaceuticals play a pivotal role in precision medicine solutions, providing innovative and promising treatments for various cancer indications. Recognizing the logistics challenges associated with radiopharmaceuticals, given their short half-lives and the critical importance of timely administration; AtomVie, together with RLS and UPPI will bolster its distribution capabilities and allow life-saving treatments to reach more patients.
“Our commitment to transforming patient lives through high-quality radiopharmaceuticals is at the core of this partnership with RLS and UPPI,” commented Bruno Paquin, CEO of AtomVie. He added “These collaborations strengthen our ability to deliver critical radiopharmaceuticals to more locations, ensuring timely access for patients who rely on the products. These partnerships not only meet the current demand but position us for future growth, as we meaningfully expand our manufacturing capacity and add commercial-scale capabilities.”
Under the agreements, AtomVie will leverage RLS’s and UPPI’s extensive radiopharmacy network, as the companies aim to swiftly deliver radiopharmaceuticals to healthcare providers.
RLS CEO Stephen Belcher expressed confidence in the partnership’s impact on patient care, stating, “Radiopharmaceuticals begin to decay very rapidly, and it is critical that they reach patients in a safe and timely manner. That’s why this partnership is so important. We are the last mile experts, and by adding our radiopharmacies to its network, AtomVie can ensure its portfolio of life-enhancing therapeutic and diagnostic radiopharmaceuticals reach the right place at the right time, every time.”
John Witkowski, President of UPPI highlighted the partnership’s impact, promoting greater accessibility and enhanced well-being for individuals, stating “This partnership is a significant step forward in improving access to life-saving radioisotope-based therapeutics and diagnostics. It reflects our joint commitment to delivering precision medicine solutions for patients across the nation.”
As leaders in their respective fields, AtomVie, RLS, and UPPI bring unique expertise to this strategic partnership, offering seamless radiopharmaceutical solutions and emphasizing their collective goal to revolutionize patient care by providing consistent access to high-quality radiopharmaceutical options nationwide.
About AtomVie Global Radiopharma Inc.
AtomVie Global Radiopharma Inc. (AtomVie) is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves international clients conducting studies in over 20 countries worldwide. AtomVie is currently building a state-of-art purpose-built, scalable facility of >70,000 sq ft in Hamilton Ontario that is set to be ready in late 2024. For more information, visit https://www.atomvie.com/
About RLS Inc.
RLS Radiopharmacies (Radioisotope Life Sciences) owns one of the largest radiopharmacy networks in the U.S., with 31 radiopharmacies covering more than 80% of the population. The company also offers an extensive portfolio of diagnostic and therapeutic radiopharmaceutical products. RLS endeavors to supply the highest quality radiopharmaceuticals in the industry by dispensing 100 percent of injectable unit dose products in clean rooms built to ISO 1644-1 specifications. In support of its commitment to quality, RLS provides tailored solutions and exceptional service to more than 1,500 customers. For more information, please visit www.rls.bio.
About UPPI LLC
Established in 1998, UPPI has become a leader in traditional nuclear medicine and in the rapidly growing field of theranostics. Representing more than 60 independent and institutional operating sites across the country, UPPI provides its members national strength in buying relationships as well as access to customizable local programs that advance the professionalism of the industry. For more information, visit: www.uppi.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/atomvie-global-radiopharma-collaborates-with-rls–uppi-to-strengthen-its-existing-us-radiotherapeutic-distribution-network-302067668.html
SOURCE AtomVie Global Radiopharma Inc.
25 March 2023; Phoenix, AZ USA UPPI President John Witkowski received the 2023 APhA Honorary Membership Award in recognition of his sustained contributions to ensuring the advancement of the nuclear pharmacy profession in the United States. The award recognized Mr. Witkowski’s decades long career in the nuclear pharmacy industry encompassing his role in sales and culminating with his current position as President of UPPI, a nationwide network of independently owned and university based radiopharmacies and cyclotrons. Of particular note was Mr. Witkowski’s work with the United States Department of Energy National Nuclear Security Administration which recognized UPPI for outstanding achievement in support of ensuring reliable supplies of molybdenum-99 produced without the use of highly enriched uranium. Under Mr. Witkowski’s leadership, UPPI’s innovation and initiative through the “LEU Walk” and other efforts demonstrated its dedication to the essential international effort to promote reliable supplies of molybdenum-99 produced without highly enriched uranium for the global marketplace. Further recognition was given by Vizient, the nation’s leading healthcare performance improvement company when it named UPPI its Distributor of the Year in 2017. Most recently, Mr. Witkowski has placed UPPI’s focus on bringing emerging theranostics to patients in the US.
UPPI is pleased to announce that it will hold its Annual Meeting in Las Vegas, NV this September. UPPI Members and Vendors are encouraged to reach out to Michelle Thompson at mthompson@uppi.org or Susan Villhauer at svillhauer@uppi.org for information regarding an agenda and hotel accommodations. Looking forward to seeing you there for talks, exhibits, networking and presentations regarding all things radiopharma!
The impact of new technology, government and international
regulations, egregious price increases, and collapsing reimbursement structures on the nuclear imaging space
March 9, 2021
Making an Impact: Innovation in the Production of Medical Radioisotopes
Session Chair: Brian Smith, Deputy Director Division of Advanced Reactors and Non-Power Production and Utilization Facilities
John Witkowski President UPPI Session Panelist
Discussion topics:
Significance of a reliable medical isotope supply chain
Mo 99 supply chain resilience in the time of COVID-19 pandemic
Challenges to establishing supply and supply chain resilience
Importance of technology innovation
Impact of medical radioisotope production on the future of the nuclear industry